Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Vitamin B3 and Reduced Amyloid Beta 42 Level

Doses used in studies

mg/day: 3,000 (median 3,000, IQR 3,000–3,000) — 1 study

Time to effect

Median: 11.2 months · IQR 11.2 months–11.2 months · Range 11.2 months–11.2 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Adverse events (AEs) were balanced by arm, with few attributed to treatment.
from: Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinami
infectionsReported
Common AEs included infections and nervous system disorders.
from: Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinami
nervous system disordersReported
Common AEs included infections and nervous system disorders.
from: Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinami

1 of 1 paper

Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.
- 2025-01-14
- RCT · n = 47
- Neurology 104(1)
- - Joshua D Grill
  - Steven Tam
  - Gaby Thai
  - Beatriz Vides
  - Aimee L Pierce
  - Kim Green
  - Daniel L Gillen
  - Edmond Teng
  - Sarah Kremen
  - Maryam Beigi
  - Robert A Rissman
  - Gabriel C Léger
  - Archana Balasubramanian
  - Carolyn Revta
  - Rosemary Morrison
  - Robin Jennings
  - Judy Pa
  - Jing Zhang
  - Shelia Jin
  - Karen Messer
  - Howard H Feldman
- PubMed: 39671543
- DOI: 10.1212/wnl.0000000000210152
8 Insights on
- Reduced Amyloid Beta 42 Level
- High evidence
- Clinical
No significant effects of treatment were observed on secondary biomarker outcomes (CSF p-tau181, Aβ40, Aβ42, and total tau) in similar models (all p values >0.05)
Effect
Neutral
Effect size
Small
Significant
No
Dose
1,500 mg twice a day (3,000 mg daily)